1. Regeneron antibody cocktail prevents COVID-19 in study — JNJ's closely watched COVID vaccine readout coming next week — GE Healthcare and Philips post earnings reports positively influenced by COVID-19 care — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice

Alphatec Spine

Discussion in 'NuVasive' started by Anonymous, Jun 15, 2009 at 8:21 PM.

  1. Anonymous

    Anonymous Guest

    What do you think of Alphatec? Should I take a position there? Are Osseofix, osseosleeve, etc going to be big? What do you think of their products now?
     
  2. Anonymous

    Anonymous Guest

    Alphatec is on the downward spiral. There is a cash flow problem. They are desperate. They are giving away huge commissions and willing to pay doctors off with offers of royalties for bogus credit on already designed products that will never see the light of day. They are killing their margins in exchange for signs of life.

    They were out of money when they went to their large institutional share holder weeks ago and shook them down for another $10 million in exchange for more useless stock. If they didn't get it, the existing stock would have been worthless. So, the gamblers coughed up the ante. That's called pouring good money after bad.
     
  3. Anonymous

    Anonymous Guest


    GUESS YOU WERE WRONG !!!!!!
     
  4. Anonymous

    Anonymous Guest

    in what way was s/he wrong? They can't keep employees, they cannot get any new products through FDA, and they can't keep key distributors. This adds up to declining revenue, after having re-stated revenue multiple times in the past. They make decent products, but have never been able to create true value as a company through any differentiation. Unless there are key dynamics that simply float spine, they are a key target for dissolution in the future, not necessarily acquisition, what would a buyer get?
     
  5. Anonymous 1

    Anonymous 1 Guest

    Guess you were wrong too!!!!
     
  6. Anonymous

    Anonymous Guest

    # Continued strong uptake and demand for PureGenTM, the Company's Osteoprogenitor Cell Allograft, with 400 cases completed by the end of first quarter 2011.
    # The SolusTM ALIF System, a zero-profile, single-action locking implant that is used in anterior lumbar interbody fusion (ALIF) procedures, received 510(k) clearance from the FDA and the Company has commenced a controlled launch in the US.

    Revenue of $49.7 million; 40.8% growth over Q1 2010;

    YEP YOU WERE WRONG!!!!!
     
  7. Anonymous

    Anonymous Guest

    400 cases in the 1st quarter? Wow. That's like 4 cases a day! Amazing sales force!!! I do four biologics cases a day in my city.. Not nationally.

    Good luck with Solus. That thing doesn't look like a deathtrap or anything. Do us all a favor and make sure that's the first thing you pull out of your bag.
     
  8. Anonymous 1

    Anonymous 1 Guest

    I don't care what they pull out of their bag or what you pull out of yours. I am interested in the stock , I picked up 20K shares @ $1.72 and were at $3.38 today, you do the math biologic boy.
     
  9. Anonymous

    Anonymous Guest

    Investor, sales rep, management, I don't really care. As long as that company has a crappy sales force and releases pathetic implants... I'd put my stock in the "Sell" category. Nothing worst than a "Me-Too" that even sucks at being that. Enjoy your retirement on all of that extra cash that's burning a hole in your pocket!

    MB